Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine, and topiramate: A comparison of the impact of age and comedication

Therapeutic Drug Monitoring

Volumn 34, Issue 4, 2012, Pages 440-445

  Johannessen Landmark, Cecilie ^a,c   Baftiu, Arton ^a,c   Tysse, Irene ^a,c   Valsø, Beate ^a,c   Larsson, Pål G ^b   Rytter, Elisif ^b   Johannessen, Svein I ^b  

^a Faculty of Health Sciences   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c OSLO METROPOLITAN UNIVERSITY   (Norway)

Author keywords

age; antiepileptic drugs; children; elderly; epilepsy; polytherapy; therapeutic drug monitoring (TDM)

Indexed keywords

CARBAMAZEPINE; CARBOXYLESTERASE; DIARYL KETONE; ETIRACETAM; FELBAMATE; GABAPENTIN; GLUCURONOSYLTRANSFERASE 1A4; GLUCURONOSYLTRANSFERASE 2B7; LAMOTRIGINE; LIVER ENZYME; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; ENZYME INHIBITION; EPILEPSY; FEMALE; GLUCURONIDATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PHARMACOKINETICS; PRESCRIPTION; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; CARBAMAZEPINE; CHILD; CHILD, PRESCHOOL; DRUG MONITORING; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; FRUCTOSE; HUMANS; MALE; MIDDLE AGED; PIRACETAM; TRIAZINES; YOUNG ADULT;

EID: 84863827127     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31825ee389     Document Type: Article

References (33)

1. Johannessen Landmark C, Larsson PG, Rytter E, et al. Antiepileptic drugs in epilepsy and other disorders: a population-based study of prescriptions. Epilepsy Res. 2009;87:31-39.
2. Johannessen Landmark C, Fossmark H, Larsson PG, et al. Antiepileptic drug use in epilepsy-a population-based study. Epilepsy Res. 2011;95:51-59.
3. Johannessen Landmark C, Patsalos PN. Drug interactions involving the new second and third generation antiepileptic drugs. Expert Rev Neurother. 2010;10:119-140.
4. Johannessen Landmark C, Johannessen SI, Tomson T. Host factors affecting antiepileptic drug delivery-pharmacokinetic variability. Adv Drug Deliv Rev. 2011, Epub ahead of print.
5. Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49:1239-1276. (Pubitemid 351991390)
6. Johannessen SI, Battino D, Berry DJ, et al. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit. 2003;25:347-363. (Pubitemid 36638181)
7. Johannessen SI, Tomson T. Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? Clin Pharmacokinet. 2006;45: 1061-1075. (Pubitemid 44631387)
8. Reimers A, Skogvoll E, Sund JK, et al. Lamotrigine in children and adolescents: the impact on its serum concentrations and on the extent of drug interactions. Eur J Clin Pharmacol. 2007;63:687-692. (Pubitemid 46911344)
9. Bengtsson F. Therapeutic drug monitoring of psychotropic drugs. TDM "nouveau". Ther Drug Monit. 2004;26:145-151. (Pubitemid 38501208)
10. Baerug AB, Tufte E, Norum KR, et al. The WHO Child Growth Standards for children under 5 years [in Norwegian]. Tidsskr Nor Laegeforen. 2007;127:2390-2394.
11. Ferrari AR, Guerrini R, Gatti G, et al. Influence of dosage, age, and co-medication on plasma topiramate concentrations in children and adults with severe epilepsy and preliminary observations on correlations with clinical response. Ther Drug Monit. 2003;35:700-708. (Pubitemid 37499304)
12. Johannessen Landmark C, Rytter E, Johannessen SI. Clinical use of anti-epileptic drugs at a referral center for epilepsy. Seizure. 2007;16:356-364. (Pubitemid 46614658)
13. Rytter E, Johannessen Landmark C, Johannessen SI. Admission of children to a referral center for epilepsy-does it make a difference? Seizure. 2009;18:573-579.
14. Perucca E. Pharmacokinetic variability of new antiepileptic drugs at different ages. Ther Drug Monit. 2005;27:714-717. (Pubitemid 44391721)
15. Hirsch LJ, Arif H, Buchsbaum R, et al. Effect of age and comedication on levetiracetam pharmacokinetics and tolerability. Epilepsia. 2007;48:1351-1359. (Pubitemid 47063068)
16. Dahlin MG, Wide K, Öhman I. Age and comedications influence levetiracetam pharmacokinetics in children. Pediatr Neurol. 2010;43:231-235.
17. Battino D, Croci D, Rossini A, et al. Topiramate pharmacokinetics in children and adults with epilepsy: a case-matched comparison based on therapeutic drug monitoring data. Clin Pharmacokinet. 2005;44:407-416. (Pubitemid 40663685)
18. Rey E, Bulteau C, Motte J, et al. Oxcarbazepine pharmacokinetics and tolerability in children with inadequately controlled epilepsy. J Clin Pharmacol. 2004;44:1290-1300. (Pubitemid 39391488)
19. Armijo JA, Vega-Gil N, Shushtarian M, et al. 10-hydroxycarbazepine serum concentration-to-oxcarbazepine dose ratio: influence of age and concomitant antiepileptic drugs. Ther Drug Monit. 2005;27:1999-2004.
20. Bartoli A, Guerrini R, Belmonte A, et al. The influence of dosage, age, and comedication on steady state plasma lamotrigine concentrations in epileptic children: a prospective study with preliminary assessment of correlations with clinical response. Ther Drug Monit. 1997;19:252-260. (Pubitemid 28053477)
21. Liston HL, Markowitz JS, DeVane CL. Drug glucuronidation in clinical psychopharmacology. Clin Psychopharmacol. 2001;21:500-515. (Pubitemid 32937433)
22. Arif H, Svoronos A, Resor SR Jr, et al. The effect of age and comedication on lamotrigine clearance, tolerability and efficacy. Epilepsia. 2011;52:1905-1913.
23. Weintraub D, Buchsbaum R, Resor SR Jr, et al. Effect of antiepileptic drug comedication on lamotrigine clearance. Arch Neurol. 2005;62:1432-1436. (Pubitemid 41352061)
24. Reimers A. Trends and changes in the clinical use of lamotrigine. Pharmacoepidemiol Drug Saf. 2009;18:132-139.
25. Reimers A, Skogvoll E, Sund JK, et al. Drug interactions between lamotrigine and psychoactive drugs: evidence from a therapeutic drug monitoring service. J Clin Psychopharmacol. 2005;25:342-348. (Pubitemid 41060254)
26. Karouni M, Arulthas S, Larsson PG, et al. Psychiatric comorbidity in patients with epilepsy: a population-based study. Eur J Clin Pharmacol. 2010;66:1151-1160.
27. Blanca Sánchez M, Herranz JL, Leno C, et al. UGT2B7--161C>T polymorphism is associated with lamotrigine concentration-to-dose ratio in a multivariate study. Ther Drug Monit. 2010;32:177-184.
28. Gulcebi MI, Ozkaynaki A, Goren MZ, et al. The relationship between UGT1A4 polymorphism and serum concentration of lamotrigine in patients with epilepsy. Epilepsy Res. 2011;95:1-8.
29. Brodie MJ, Sills GJ. Combining antiepileptic drugs-rational polytherapy? Seizure. 2011;20:369-375.
30. Contin M, Riva R, Albani F, et al. Topiramate therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. Ther Drug Monit. 2002;24:332-337. (Pubitemid 34553196)
31. Contin M, Albani F, Riva R, et al. Levetiracetam therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. Ther Drug Monit. 2004;26:375-379. (Pubitemid 38989656)
32. Johannessen SI. Pharmacokinetics and interaction profile of topiramate: review and comparison with other newer antiepileptic drugs. Epilepsia. 1997;38(suppl 1):S18-S23. (Pubitemid 27150608)
33. Johannessen Landmark C, Johannessen SI. Drug safety aspects of anti-epileptic drugs - focus on pharmacovigilance. Pharmacoepidemol Drug Saf. 2012;21:11-20.